BFM
RLAY icon

Boothbay Fund Management’s Relay Therapeutics RLAY Stock Holding History

Boothbay Fund Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,900
Closed -$249K – 2167
2021
Q3 		$249K Buy
+7,900
New +$266K 0.01% 1436

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boothbay Fund Management's RLAY Position: Q4 2025 in Review

Boothbay Fund Management sold out of Relay Therapeutics (RLAY) in Q4 2025, closing a stake of 137,841 shares — an estimated $720K sold.

Boothbay Fund Management first reported a position in RLAY in Q3 2024 and held it in 5 quarters. The position peaked at $1.48M in Q3 2024. 226 funds tracked by Wall St. Rank hold RLAY as of Q4 2025.

  • Boothbay Fund Management reported no remaining Relay Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 137,841 Relay Therapeutics shares in Q4 2025, an estimated $720K.
  • Boothbay Fund Management first reported a position in Relay Therapeutics in Q3 2024 and held it in 5 quarters.
  • Boothbay Fund Management's Relay Therapeutics position peaked at $1.48M in Q3 2024.
  • 226 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.